Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-3750 in Mild to Moderate Ulcerative Colitis
NCT05666960Phase 1Recruiting
- Sponsor
- Rise Therapeutics
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R-3750 in ulcerative colitis (UC), sponsored by Rise Therapeutics. Primary endpoint: Tolerability at 6 weeks. Started Feb 2023; status: recruiting.
02
Drugs
R-3750
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05666960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666960.